Hybrid Immunity to SARS-CoV-2 in Immunocompromised Children
Author Information
Author(s): Youjia Zhong, Kottaiswamy Amuthavalli, Ang Chen Xiang, Li Hui’ En, Yap Gaik Chin, Tay Carina J. X., Osman Nurul Elyana, Roslan Siti Namirah Binte, Tan Chee Wah, Yap Wee Chee, Ang Elizabeth Y., Chan Ng Pauline P. L., Yap Hui Kim, Lu Liangjian, Aw Marion M., Karthik Sivaraman V., Quak Seng Hock, Quah Thuan Chong, Tham Elizabeth H., Shek Lynette P., Ooi Eng Eong
Primary Institution: National University of Singapore
Hypothesis
What is the durability of hybrid immunity to SARS-CoV-2 in immunocompromised children compared to healthy children?
Conclusion
Immunocompromised children may benefit from a 3-dose primary vaccination regime, with yearly or twice-yearly booster doses for sustained immunity.
Supporting Evidence
- Immunocompromised children had significantly lower antibody responses after two vaccine doses compared to healthy children.
- A third vaccine dose improved T cell responses in immunocompromised children.
- By month 12, most immunocompromised children had T cell and memory B cell responses below protective thresholds.
- Hybrid immunity was initially robust in immunocompromised children but declined significantly over time.
Takeaway
Kids with weak immune systems need extra vaccine doses to stay safe from COVID-19, especially after their first shots wear off.
Methodology
A prospective cohort study comparing vaccine responses in immunocompromised children and healthy children over 12 months.
Potential Biases
The cohort was heterogeneous in terms of underlying disease and immunosuppressants received.
Limitations
The study had a small sample size and did not assess mucosal immunity.
Participant Demographics
Immunocompromised children aged 5-12 years, including those post-organ transplantation and on chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website